The Tumor Mutational Burden (TMB) Subcommittee provides expert guidance and recommendations regarding scientific biology, technologies and practices relating to TMB as a quantitative genomic biomarker for personalized medicine in the cancer immunotherapy setting.
Chairs
Jianda Yuan, MD, PhD
Merck Research Laboratories
Priti S. Hegde, PhD
Foundation Medicine